A retrospective cohort analysis by Riley et al. [73] found that GLP-1 RA and/or SGLT2i significantly reduced the risk of cardiovascular diseases such as acute myocardial infarction, heart failure, hospitalization risk, and all-cause mortality in T2DM patients compared with those receiving insulin alone. Here, GLP1R is linked to cardiovascular disorder.